Skip to main content
Search
News, Views, and Advocacy From the Oncology Nursing Society
ONS Voice Home
  • News & Views
  • Advocacy
  • Stories
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • News & Views
    • Latest Articles
    • Clinical Practice
    • ONS News
    • ONS Leadership
    Trending Topics
    • Treatments
    • Research
    • Safety
    • ONS Congress
    • Clinical practice
    • U.S. Food and Drug Administration (FDA)
    View All Topics
    Advocacy
    • Latest Articles
    • Updates
    • Get Involved
    Stories View All
    View All
    Experience the Power of Patient-Centered Research Through PCORI
    Health Policy
    Experience the Power of Patient-Centered Research Through PCORI
    February 07, 2019
    Building Collaboration, Education With Oncology Nurses in Malawi
    Oncology nursing community
    Building Collaboration, Education With Oncology Nurses in Malawi
    January 30, 2019
    Reality-Based Leadership Helps Nurses Cut the Drama So They Can Problem Solve
    Nurse self-care
    Reality-Based Leadership Helps Nurses Cut the Drama So They Can Problem Solve
    December 18, 2018
    ONS Members Share Education, Resources in Peru
    Oncology nursing community
    ONS Members Share Education, Resources in Peru
    November 16, 2018
    This Week, Recognize and Thank Your Oncology Nurse Practitioner Colleagues
    Advanced practice nursing (APN)
    This Week, Recognize and Thank Your Oncology Nurse Practitioner Colleagues
    November 12, 2018
    previous slide
    next slide
    Search
  • News & Views
  • Advocacy
  • Stories
  • Topic

    Genetics & genomics

    Epigenetic Cervical Cancer Test May Be More Accurate Than Pap or HPV Tests
    Genetics & genomics

    Epigenetic Cervical Cancer Test May Be More Accurate Than Pap or HPV Tests

    An S5 methylation test detected 100% of grade 2 cervical intraepithelial neoplasms or worse, compared to a 50% detection rate for Pap or human papillomavirus (HPV) tests, according to the results of a recent study reported in the International Journal of Cancer.

    February 13, 2019
    BRCA Is Not the Only Common Mutation for Breast and Ovarian Cancer
    Research

    BRCA Is Not the Only Common Mutation for Breast and Ovarian Cancer

    Multigene testing for hereditary breast and ovarian cancer has increased the detection predisposition genes beyond BRCA1 and BRCA2, according to study findings presented at the San Antonio Breast Cancer Symposium on December 7, 2018. 

    January 02, 2019
    San Antonio Breast Cancer Symposium

    Trastuzumab Remains Standard HER2+ Breast Cancer Therapy Despite Cardiac Risks

    Trastuzumab can improve disease-free survival (DFS) and overall survival (OS) in patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer. Although some studies suggest that short-term treatment (less than one year) may reduce cardiac toxicity and cost without compromising outcomes, the results of a new study presented at the San Antonio Breast Cancer Symposium on December 8, 2018, disagree.

    December 10, 2018
    San Antonio Breast Cancer Symposium

    On-Treatment Genetic Testing Improves Accuracy of Tumor Response Prediction

    Genetic testing during treatment can improve accuracy of response and outcome prediction compared to other prognostic tests, according to results from a study assessing on-treatment changes in gene expression in patients receiving chemotherapy. Researchers from Oikonomidou O Institute of Genetics and Molecular Medicine in Edinburgh, United Kingdom, presented the findings at the San Antonio Breast Cancer Symposium on December 6, 2018.

    December 06, 2018
    American Society of Hematology Annual Meeting

    Genetics Plays a Role in Treatment Response for Relapsed or Refractory Multiple Myeloma

    No molecular-informed personalized therapies are currently available for patients with relapsed/refractory multiple myeloma (MM); however, cytogenetics and next-generation sequencing (NGS) can identify molecular abnormalities to provide guidance for more targeted therapy. Tarek Assi, MD, of Gustave Roussy Cancer Campus in Villejuif, France, discussed his research team’s findings that tumor genotyping is associated with higher response rates and prolonged duration of therapy at the ASH Annual Meeting on December 1, 2018.

    December 01, 2018
    FDA Approves Larotrectinib for Solid Tumors With NTRK Gene Fusions
    U.S. Food and Drug Administration (FDA)

    FDA Approves Larotrectinib for Solid Tumors With NTRK Gene Fusions

    On November 26, 2018, the U.S. Food and Drug Administration (FDA) granted accelerated approval to larotrectinib for adult and pediatric patients with solid tumors that have a neurotrophic receptor tyrosine kinase (NTRK) gene fusion without a known acquired resistance mutation, that are either metastatic or where surgical resection is likely to result in severe morbidity, and who have no satisfactory alternative treatments or whose cancer has progressed following treatment.

    November 27, 2018
    Which Gene is Associated With Cowden Syndrome (Multiple Hamartoma Syndrome)?
    Genetics & genomics

    Which Gene Is Associated With Cowden Syndrome (Multiple Hamartoma Syndrome)?

    Which Gene is Associated With Cowden Syndrome (Multiple Hamartoma Syndrome)?

    A. APC 

    B. VHL 

    C. TP53 

    D. PTEN

    October 05, 2018
    Biosimilars and Gene Therapy Are Making Great Strides in Cancer Care
    U.S. Food and Drug Administration (FDA)

    Biosimilars and Gene Therapy Are Making Great Strides in Cancer Care

    As researchers learn more about how combination therapy combats drug resistance and lessens the changes of tumor evasion of the immune system, immune checkpoint inhibitors are receiving approval for a broader range of indications. However, recent U.S. Food and Drug Administration (FDA) approvals have centered around hematologic malignancies and the emergence of two new biosimilars. 

    September 25, 2018
    How Patients Can Benefit From Hereditary Cancer Support
    Genetics & genomics

    How Patients Can Benefit From Hereditary Cancer Support

    My story, like many of your patients, is unfortunately not that uncommon: I’m a motherless daughter. I lost my mom to breast cancer when I was 26 years old; she lost her mother to the disease before she graduated high school. The BRCA1 mutation has been passed down in my family, and I, too, carry the mutation. Even though it was expected, I was devastated and desperately looking for resources to help manage my cancer risk. It was scary not knowing where to turn. I needed to know that I wasn’t alone. 

    September 18, 2018
    NINR Study Identifies Genes for Fatigue in Cancer Treatment
    Genetics & genomics

    NINR Study Identifies Genes for Fatigue in Cancer Treatment

    Radiation therapy can be an incredibly draining form of treatment for patients with cancer. Side effects such as fatigue can be debilitating for many before, during, and after treatment. Because symptom management is a crucial component to cancer care and central role of oncology nursing, ensuring that patients are able to mitigate their symptoms and side effects can help improve their quality of life. Recently, a team at the National Institute of Nursing Research (NINR) identified certain genes associated with fatigue in men being treated for prostate cancer.

    August 29, 2018
    ONS Congress

    Genomics Is Revolutionizing Cancer Care Now and For the Future

    As precision oncology continues to expand, so does the ability to use less-toxic targeted therapies. James Chen, MD, assistant professor of biomedical informatics and assistant professor of internal medicine at the division of medical oncology at Ohio State University in Columbus, described his work with genomics in cancer care and the challenges in precision medicine at the 43rd Annual Congress in Washington, DC.

    July 11, 2018
    Why Pretesting Counseling Is Critical in the Age of Consumer Genetic Tests
    Genetics & genomics

    Why Pretesting Counseling Is Critical in the Age of Consumer Genetic Tests

    On March 6, 2018, 23andMe—an at-home genetic testing company—announced their direct-to-consumer genetic test (DTCGT) would include DNA results for the three common founder BRCA mutations commonly seen in people with Ashkenazi Jewish ancestry. This was big news because DNA results for the BRCA mutations had been previously available on the 23andMe panel report until the U.S. Food and Drug Administration removed them in 2013.

    July 06, 2018
    New Gene-Based Tests Screen and Monitor for Bladder, Endometrial, and Ovarian Cancers
    Genetics & genomics

    New Gene-Based Tests Screen and Monitor for Bladder, Endometrial, and Ovarian Cancers

    Researchers have developed two new gene-based tests that detect DNA mutations that lead to bladder, endometrial, and ovarian cancers. The tests, which are not yet U.S. Food and Drug Administration approved, could be used to identify a new or relapsed cancer earlier, when it is easier to treat.

    June 27, 2018
    ASCO Annual Meeting

    Study Gives a Better Understanding of ARID1A Mutations in Colorectal Cancer

    A component of the SWI/SNF chromatin remodeling complex, AT-rich interactive domain 1A (ARID1A), regulates gene expression. Data on the characteristics and associated clinicopathologic features of ARID1A in colorectal cancer (CRC) are limited, even though its mutations are reported in a variety of other cancers. In study findings presented at the 2018 American Society of Clinical Oncology Annual Meeting, researchers explained an increased understanding of the ARID1A mutation in CRC.

    June 03, 2018
    BRCA Mutations Point to Hereditary Breast and Ovarian Cancer Syndrome
    Genetics & genomics

    BRCA Mutations Point to Hereditary Breast and Ovarian Cancer Syndrome

    Although all cancers have a genetic basis, a subset result from an inherited (i.e., germline) mutation that puts a person at increased risk for certain cancers. Unfortunately, the signs of hereditary cancer are often overlooked or misunderstood. Here’s what oncology nurses need to know about BRCA mutations, one of the more common mutations you’ll see in practice.

    May 24, 2018
    Which Genetic Test Performed on Tumor Cells Has Prognostic and Predictive Uses?
    Genetics & genomics

    Which Genetic Test Performed on Tumor Cells Has Prognostic and Predictive Uses?

    Which Genetic Test Performed on Tumor Cells Has Prognostic and Predictive Uses? 

    A. BRCA1 test 

    B. CA 27.29 

    C. Circulating tumor cells

    D. Oncotype DX® 

    May 24, 2018
    ONS Congress

    Understanding Genomics and Using Precision Medicine to Advance Cancer Survival

    During the American Association for Cancer Research/ONS Bench to Bedside session at the 43rd Annual Congress in Washington, DC, Victor Velculescu, MD, PhD, of Johns Hopkins University School of Medicine, and Maura Kadan, RN, MSN, of Personal Genome Diagnostics, dissected the science behind precision oncology, including an understanding of genetic alterations, the use of immunotherapy, and how to advance survival with these clinical breakthroughs.

    May 19, 2018
    NIH Wants 1 Million Americans to Contribute to New Pool of Gene Data; FDA Takes Action Against Misleading Companies Marketing to Kids; Conservative Groups Hope to Release New Obamacare Replacement This Month
    Genetics & genomics

    NIH Wants 1 Million Americans to Contribute to New Pool of Gene Data; FDA Takes Action Against Misleading Companies Marketing to Kids; Conservative Groups Hope to Release New Obamacare Replacement This Month

    With hopes for more than 1 million participants, the National Institutes of Health (NIH) has launched the All of Us initiative, a radical precision medicine campaign to amass a collective gene pool data repository. The NIH is aiming to shrink our differences and expand on the similarities found in our genetic data. For some, compiling genetic data of an entire country’s citizens may sound very reminiscent of Big Brother from the book 1984. But the amount of information that could be shared and learned from such a massive health database is remarkable.

    May 07, 2018
    FDA
    U.S. Food and Drug Administration (FDA)

    FDA Approves Dabrafenib Plus Trametinib for Adjuvant Treatment of Melanoma With BRAF V600E or V600K Mutations

    On April 30, 2018, the U.S. Food and Drug Administration (FDA) granted regular approval to dabrafenib (Tafinlar ®) and trametinib (Mekinist®) in combination for the adjuvant treatment of patients with melanoma with BRAF V600E or V600K mutations, as detected by an FDA-approved test, and involvement of lymph node(s), following complete resection.

    April 30, 2018
    Which Gene Plays a Role in Tumor Resistance?
    Chemotherapy

    Which Gene Plays a Role in Tumor Resistance?

    Which of the following is gene that may play a role in tumor resistance to chemotherapy?

    A. NRAS

    B. APC

    C. p53

    D. VHL

    April 26, 2018
    How DNA Revolutionized Oncology Care
    Genetics & genomics

    How DNA Revolutionized Oncology Care

    April 25, 2018, marks National DNA Day. Why the hype? National DNA Day commemorates the successful completion of the Human Genome Project in 2003, and the discovery of DNA's double helix in 1953. Without DNA, understanding the diseases and treatments for cancer would be nearly impossible. Genetics and genomics play huge roles in treating malignancy, and it’s crucial to the care of patients with cancer for oncology nurses to understand genetics and genomics.

    April 25, 2018
    Labs Differ Widely in BRCA Testing Protocols
    Genetics & genomics

    Labs Differ Widely in BRCA Testing Protocols

    An international survey of 86 genetic testing labs showed inconsistent protocols and standards for analyzing the BRCA1 or 2 cancer susceptibility genes and their variations. The results were reported in NPJ Genomic Medicine.

    April 18, 2018
    NIH Completes In-Depth Genomic Analysis
    Genetics & genomics

    NIH Completes In-Depth Genomic Analysis; Senate Panel Unveils Draft Opioid Bill; Teenagers Struggle to Quit Vaping

    Researchers for the PanCancer Atlas, a genomic data set reference tool, recently completed an analysis of molecular and clinical information from more than 10,000 different tumors spanning more than 33 cancer types. The PanCancer Atlas is the result of nearly a decade’s worth of work associated with the Cancer Genome Atlas—a multi-institutional program driven by the National Human Genome Research Institute and the National Cancer Institute (NCI). The results of the analysis were published as a set of 27 papers.

    April 09, 2018
    FDA Authorizes Direct-to-Consumer Test for BRCA Cancer Gene
    U.S. Food and Drug Administration (FDA)

    FDA Authorizes Direct-to-Consumer Test for BRCA Cancer Gene

    Genetic testing is becoming more recognized among the general public, due in part to news reports and celebrity endorsements. Now, people are seeking to understand cancer risks and prevention measures through genetic information. There are many companies that ask for a mere mouth swab and deliver insight into a person’s DNA. As this becomes more commonplace, those with familial predisposition to cancer will look for ways to understand their own genetic results. Recently, the U.S. Food and Drug Administration (FDA) approved an at-home test identifying some—but not all—breast cancer genes.

    April 02, 2018
    Oncology Nurses Play Key Role in Genetics Education, Testing for Patients
    Genetics & genomics

    Oncology Nurses Play Key Role in Genetics Education, Testing for Patients

    Identifying genetically predisposed women with breast cancer who could benefit from risk assessment and genetic counseling is an important competency for oncology nurses. However, a recent study published in the Journal of Clinical Oncology (JCO) reported that fewer than 50% of newly diagnosed patients with breast cancer who should have been given formal genetic counseling actually received the appropriate genetic testing.

    March 29, 2018
    Newly Approved Cancer Treatments Indicate Growing Role of Genomics and Oral Therapies
    U.S. Food and Drug Administration (FDA)

    Newly Approved Cancer Treatments Indicate Growing Role of Genomics and Oral Therapies

    It is becoming more commonplace for nurses to find orders for agents with which they are unfamiliar or quite possibly have never administered. Following is a summary of the latest new U.S. Food and Drug Administration (FDA) approvals or indications to keep you up to date in your practice. Of note, this summary contains the approval of yet another biosimilar in trastuzumab-dkst and rolapitant for chemotherapy-induced nausea and vomiting, which includes a safety alert. Early experiences with rolapitant, a NK-1 inhibitor, indicated a risk of hypersensitivity reactions.

    March 28, 2018
    Two Bacteria Species Connected to Certain Colon Cancers
    Research

    Two Bacteria Species Connected to Certain Colon Cancers

    Bacteroides fragilis and Escherichia coli appear to collaborate to promote hereditary and sporadic colon cancers, according to the results of studies published in Cell Host and Microbe and Science.

    March 21, 2018
    Oncology Nurses Can Help Patients Understand At-Home Genetic Testing
    Genetics & genomics

    Oncology Nurses Can Help Patients Understand At-Home Genetic Testing

    Direct-to-consumer genetic testing (DTCGT) has entered the prime-time stage. It’s difficult to watch TV without seeing ads touting the simplicity of DTCGT and what it can tell you, and it even made Oprah’s 2017 Favorite Things List.

    March 14, 2018
    What Oncology Nurses Need to Know About Pharmacogenomics
    Clinical practice

    What Oncology Nurses Need to Know About Pharmacogenomics

    A subset of precision medicine, pharmacogenomics, is also growing exponentially, especially in oncology. Currently, 165 drugs or combinations are influenced by pharmacogenetics, and 58 of those are specific to oncology/hematology.

    March 13, 2018
    NIH Devotes Funding to Precision Research for Childhood Cancer
    Research

    NIH Funds Precision Research for Childhood Cancer; Will Congress Lift Medicaid Ban for Opioid Epidemic?; FDA-Approved Breast Cancer Test May Impact Oncology Nurses

    Cancer treatments aren’t one-size-fits-all, and they differ greatly depending on age.  As the leading cause of disease-related death for children, pediatric cancers pose a critical threat to this population. According to the National Institutes of Health (NIH), one reason pediatric cancer mortality rates persist is because there’s “limited knowledge” related to the biological mechanisms affecting childhood cancers. NIH-funded studies are breaking ground and uncovering new information about the genomics of pediatric cancers.

    March 12, 2018
    The Case of the Cancer Genetics Referral
    Clinical practice

    The Case of the Cancer Genetics Referral

    Christina is a 29-year-old African American woman with a strong family history of breast and ovarian cancers and a personal history of benign ovarian fibroids. She was referred to your office because of a suspicious lump in her left breast. Because of her family history, Christina is especially worried. You are concerned that Christina could have a hereditary family cancer syndrome, and you know that a comprehensive family history must be obtained.

    February 19, 2018
    NIH: A Look Back at 2017 in Research
    Research

    NIH: A Look Back at 2017 in Research

    To plan for a strong future, one must understand the past. Reviewing the previous year’s accomplishments is always a good policy for reflection and improvement. It can help remind us of the accomplishments achieved in 12 short months. Such was the case at the National Institutes of Health (NIH), as director Francis Collins addressed the research achievements for 2017 in his opening blog.

    January 30, 2018
    FDA Clears Genomic Profiling Tests for Cancer Treatment
    U.S. Food and Drug Administration (FDA)

    FDA Clears Genomic Profiling Tests for Cancer Treatment

    Former National Institutes of Health (NIH) Director, Harold Varmus, when asked about cancer treatment, once said, “One of the major advances we’ve had as a result of cancer research is deep recognition of the complexity of cancer. It’s not one disease, it’s lots of different diseases. Every single cancer is different when you look at it on a genetic level.”

    January 29, 2018
    San Antonio Breast Cancer Symposium

    Latinas With BRCA1 or 2 Mutations Are More Likely to Choose Surgery

    The uptake of prophylactic surgeries among Latinas with germline BRCA mutations may be slightly lower than what has been reported in non-Hispanic whites but higher than in African Americans, a group of U.S. researchers said. They presented their findings on Saturday, December 10, during a poster session at the San Antonio Breast Cancer Symposium.

    December 10, 2017
    San Antonio Breast Cancer Symposium

    Enrichment of Mucin Gene Family Shown in Breast Cancer Diagnosed During Pregnancy

    The first study on the mutational landscape of breast cancer diagnosed during pregnancy (BCP) using whole-genome sequencing found that BCP is associated with a higher number of putative driver mutations, including mutations in mucin genes. Researchers presented their findings on Thursday, December 7, during a poster session at the San Antonio Breast Cancer Symposium.

    December 07, 2017
    fda update
    U.S. Food and Drug Administration (FDA)

    FDA Grants Marketing Approval to FoundationOne CDx In Vitro Diagnostic

    On November 30, 2017, the U.S. Food and Drug Administration granted marketing approval to the FoundationOne CDx, a next generation sequencing based in vitro diagnostic to detect genetic mutations in 324 genes and two genomic signatures in any solid tumor type.

    November 30, 2017
    Study Finds How Smoking Contributes to Epigenetics of Lung Cancer
    Lung Cancer

    Study Finds How Smoking Contributes to Epigenetics of Lung Cancer

    Although cigarette use has long been linked to lung cancer, scientists have not understood how the earliest changes in lung cells developed. In a study published in Cancer Cell, researchers showed how cigarette smoke sensitized airway cells to genetic mutations that are known to cause lung cancers.

    November 22, 2017
    Late side effects of immunotherapy
    Immunotherapy

    The Case of the Slow-to-Manifest Side Effects

    Mary, age 60, has been diagnosed with stage IIB ovarian cancer. Because she has a strong family history of various cancers, Mary is tested for Lynch syndrome, also known as hereditary nonpolyposis colorectal cancer (HNPCC).

    Her test is positive, and she is told she is at increased risk for developing cancers associated with HNPCC: ovarian, breast, prostate, kidney, endometrial, pancreatic, prostate, and liver.

    November 14, 2017
    Oncology Nurses Need to Embrace Genetics
    Genetics & genomics

    Why Oncology Nurses Need to Embrace Genetics

    Genetics in clinical oncology nursing practice permeates all aspects of care from prevention and detection to treatment decisions to long-term survivorship care. Each of these areas often overlap, and oncology nurses need a solid genetics understanding to provide optimal care.

    October 23, 2017
    Researchers Map More Than 760 Cancer-Dependent Genes
    Research

    Researchers Map More Than 760 Cancer-Dependent Genes

    In an effort to build a comprehensive catalog of genetic causes of cancer, researchers from Harvard and Massachusetts Institute of Technology’s Broad Institute as well as Dana-Farber Cancer Institute have identified more than 760 genes that cells from multiple types of cancer depend on for growth and survival. The findings were published in Cell.

    October 04, 2017
    Capitol Hill
    Affordable Care Act (ACA)

    Sanders Gains Support for Single-Payer Health Care Push; GOP Senators Put Forth Graham-Cassidy Healthcare Bill; New Toolkit Helps Nurses Integrate Genomics in Cancer Care

    Senator Bernie Sanders (I-VT) recently gave an interview for The Nation to discuss his announcement and subsequent push for a single-payer healthcare system in the United States. During his 2016 presidential bid, Sanders campaigned for universal health care and gained significant support from the public. However, many on Capitol Hill were still unsure of a “Medicare-for-all” plan. Despite the initially tepid response, Sanders recently outlined a new single-payer healthcare bill he plans to introduce, and he’s gaining surprising support from several senators in Washington, DC.

    September 25, 2017
    FDA Update
    U.S. Food and Drug Administration (FDA)

    FDA Approves First Single NGS Test to Detect Multiple RAS Mutations

    On June 29, 2017, the U.S. Food and Drug Administration (FDA) granted marketing approval to the Praxis Extended RAS Panel (Illumina, Inc.), a next generation sequencing (NGS) test to detect certain genetic mutations in RAS genes in tumor samples of patients with metastatic colorectal cancer (mCRC). The test is used to aid in the identification of patients who may be eligible for treatment with panitumumab (Vectibix®, Amgen, Inc.).

    July 05, 2017
    ONS Congress

    Genomic Information Helps Guide Successful Therapies for Each Patient

    The healthcare landscape is changing more rapidly than ever, and daily discoveries in genomics are leading to truly individualized care. During a session at the 42nd Annual Congress in Denver, CO, David Solit, MD, Geoffrey Beene Chair and director of the Marie-Josée and Henry R. Kravis Center for Molecular Oncology at Memorial Sloan Kettering Cancer Center (MSKCC), reviewed cutting-edge genomics science, its role in precision medicine, and innovative genomics programs at his institution. Solit leads a research program that seeks to identify new drug targets using genomic profiling.

    July 03, 2017
    supportive oncology services
    Cancer screening

    Local Organizations Can Make a Big Difference in Cancer Care

    I have the privilege of managing and being the sole provider in a unique program. I work in the Hereditary Cancer Program at Saint Louis University Cancer Center, where I provide risk assessment services and education about genetic testing to individuals and families in the region. It’s an amazing nursing role, and I can truly help people prevent cancer and manage their risk.

    June 28, 2017
    BRCA Testing
    Genetics & genomics

    More Women Undergo BRCA Testing, but Not High-Risk Patients

    BRCA gene testing is on the rise for women who do not meet the referral requirements based on family history, researchers reported in study findings published in the American Journal of Preventive Medicine. At the same time, many high-risk women do not obtain the test and remain unidentified.

    June 14, 2017
    DNA Copying Causes Most Cancer Mutations
    Cancer research

    Random DNA Copying Causes Most Cancer Mutations

    Researchers at Johns Hopkins Kimmel Cancer Center have demonstrated that random, unpredictable DNA copying mistakes account for nearly two-thirds of the mutations that cause cancer. The results were reported in Science.

    June 07, 2017
    ASCO Annual Meeting

    Genetic Screening Tool Identifies Women With BRCA Mutations Who May Have Been Otherwise Missed

    Researchers sought to assess the value of breast imaging centers (BICs) as potential clinics to identify women who are at high risk for hereditary breast and ovarian cancer (HBOC) and increase the number of appropriate referrals for genetic assessment. The researchers’ hospital-based BIC serves mostly low- to middle-income patients in a major metropolitan area. They developed a practical screening tool based on the National Comprehensive Cancer Network HBOC screening and testing guidelines and prospectively screened patients. The researchers presented their findings at the ASCO Annual Meeting.

    June 05, 2017
    CAR T-Cell Immunotherapy
    Cancer research

    Gene-Editing Tool May Better Deliver CAR T-Cell Immunotherapy

    In mouse experiments, researchers have found that immune T cells that have been genetically engineered to express chimeric antigen receptors (CARs) using a new tool called CRISPR were more effective than CAR T cells that were engineered with conventional methods. The findings were reported in Nature.

    May 24, 2017
    Double Helix
    Genetics & genomics

    The Story of Henrietta Lacks Sheds Light on Ethical Considerations in Genetic Testing

    Imagine a situation where a patient’s tumor cells were used for countless scientific experiments—without the patient’s informed consent. Safeguards are in place today to prevent such an ethical breach, but in 1951 Henrietta Lacks and her family weren’t as lucky. Author Rebecca Skloot shared Henrietta’s story in a 2010 nonfiction book, The Immortal Life of Henrietta Lacks, that was adapted into a movie released on April 22, 2017.

    April 28, 2017
    FDA Update
    U.S. Food and Drug Administration (FDA)

    FDA Approves Marketing Ipsogen JAK2 RGQ PCR Kit to Help Evaluate Suspected Polycythemia Vera

    The U.S. Food and Drug Administration has granted marketing authorization to ipsogen JAK2 RGQ PCR Kit, manufactured by Qiagen GmbH., to detect mutations affecting the Janus Tyrosine Kinase 2 (JAK2) gene. This is the first FDA-authorized test intended to help physicians in evaluating patients for suspected Polycythemia Vera (PV).

    April 07, 2017
    • Current page 1
    • Page 2
    • Next page
    • Last page Last »
    Trending Topics
    • Treatments
    • Research
    • Safety
    • ONS Congress
    • Clinical practice
    • U.S. Food and Drug Administration (FDA)
    • Immunotherapy
    • Health Policy
    • Cancer research
    • Symptom management
    View All Topics
    Home
    News, Views, and Advocacy From the Oncology Nursing Society
  • Legal Notices
  • Contact Us
  • Conferences
  • Advertising
  • Sitemap
  • Instagram
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • RSS
  • ONS
  • Oncology Nursing Foundation
  • ONCC
  • © Copyright 2019 Oncology Nursing Society
    Back to Top ▲